Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir

doi:10.3748/wjg.v20.i23.7169

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 23

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5703)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

360

WORD

245

HTML

3187

Tables (1-4)

220

Sum=4012

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

933

Download

758

Sum=1691

Jun 21, 2014 (publication date) through Aug 25, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jun 21, 2014; 20(23): 7169-7180
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7169

Table 4 Summary of efficacy results from real-life studies of tenofovir in nucleos(t)ide analogue-naïve patients n (%)

Study	Median follow-up (range)	Patients(n)	Cut-off (assay limit) (IU/mL)	HBV DNA undetectable¹	HBeAg seroconversion¹²	HBsAg loss¹
King’s College cohort[24]	12 mo	60	12	33 (76)	2 (7)	0
United States cohort[38]	12 mo (6-23 mo)	28	100	23 (82)	7 (5)	0
European cohort[42]	33 mo (0-66 mo)	302	12	91 (97)	18 (36)³	8 (13)
German cohort[43]	24 mo	184	69	170 (92)	NR	NR

¹Unless stated otherwise;

²among those hepatitis B e antigen (HBeAg) (+) at baseline;

³Kaplan–Meier estimate. NR: Not reported; HBV: Hepatitis B virus; NR: Not reported; NUC: Nucleos(t)ide analogue; HBsAg: Hepatitis B surface antigen.

Citation: Ridruejo E. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. World J Gastroenterol 2014; 20(23): 7169-7180
URL: https://www.wjgnet.com/1007-9327/full/v20/i23/7169.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i23.7169